{{Rsnum
|rsid=6922548
|Gene=PPARD
|Chromosome=6
|position=35385746
|Orientation=plus
|GMAF=0.2094
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PPARD
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 85.8 | 12.4 | 1.8
| HCB | 91.2 | 8.8 | 0.0
| JPT | 92.0 | 8.0 | 0.0
| YRI | 6.1 | 38.1 | 55.8
| ASW | 19.3 | 40.4 | 40.4
| CHB | 91.2 | 8.8 | 0.0
| CHD | 96.3 | 3.7 | 0.0
| GIH | 92.1 | 7.9 | 0.0
| LWK | 6.4 | 37.3 | 56.4
| MEX | 89.7 | 10.3 | 0.0
| MKK | 19.9 | 53.8 | 26.3
| TSI | 80.4 | 19.6 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6922548
|Name_s=PPARD:rs6922548 A>G;
|Gene_s=PPARD
|Feature=
|Evidence=PubMed ID:20038957
|Annotation=Risk or phenotype-associated allele: G Phenotype: The PPAR delta SNP rs6922548 A>G was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0011 Type of association: PD; CO
|Drugs=docetaxel; thalidomide
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165111523
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6922548
|overall_frequency_n=30
|overall_frequency_d=112
|overall_frequency=0.267857
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=28
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}